8-K: SpringWorks Therapeutics Announces Preliminary Q4 and Full Year 2024 Financial Results, Anticipates Profitability in First Half of 2026

SpringWorks Therapeutics reports strong preliminary revenue for OGSIVEO and a solid cash position, projecting profitability by the first half of 2026.

Summary

• SpringWorks Therapeutics announced preliminary unaudited financial results for the fourth quarter and full year 2024.
• The company achieved $61.5 million in preliminary U.S. net product revenue for OGSIVEO in Q4 2024.
• Full year 2024 preliminary U.S. net product revenue for OGSIVEO reached $172.0 million.
• As of December 31, 2024, SpringWorks had approximately $461.9 million in cash, cash equivalents, and marketable securities.
• The company anticipates achieving profitability in the first half of 2026.
• SpringWorks plans to secure regulatory approval for OGSIVEO in the European Union and launch in individual EU countries, starting with Germany in mid-2025.
• The company expects to secure FDA approval for mirdametinib in adults and children with NF1-PN by February 28, 2025, and launch in the U.S.
• An Investigational New Drug (IND) application for SW-3431 is expected to be filed by the end of 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a healthy cash position, and anticipated profitability. The pipeline advancements and potential product launches further contribute to the positive sentiment.

Positives

• Strong OGSIVEO revenue indicates successful commercial execution.
• Solid cash position provides runway to profitability.
• Positive long-term data from the DeFi trial supports the continued use of nirogacestat.
• The licensing agreement for SW-3431 expands the pipeline with a promising new asset.
• Anticipated FDA approval and launch of mirdametinib represents a significant milestone.
• Planned EU launch of OGSIVEO expands market reach.

Negatives

• The financial results are preliminary and unaudited, subject to change.
• The company's profitability is not expected until the first half of 2026.

Risks

• Commercialization efforts for OGSIVEO may not be successful.
• The company has limited experience as a commercial company.
• Obtaining and maintaining adequate coverage and reimbursement for OGSIVEO may be challenging.
• Clinical trials may not be successful or completed on time.
• Regulatory approvals may be delayed or not received.
• The company may not be able to maintain adequate patent protection.
• The company may not be able to establish manufacturing capabilities or scale production.

Future Outlook

SpringWorks anticipates a transformative year in 2025 with the potential launch of mirdametinib and global expansion of OGSIVEO, expecting to achieve profitability in the first half of 2026.

Management Comments

• Saqib Islam, Chief Executive Officer of SpringWorks, stated that 2025 is set up to be another transformative year for SpringWorks.
• He also mentioned that the company is energized by the opportunity to continue delivering on the commitments they have made to the patient communities they are dedicated to serving.
• He added that the company is advancing its pipeline of oncology programs and is confident that its strong foundation will drive long-term growth and success.

Industry Context

SpringWorks' focus on rare diseases and cancer aligns with the broader industry trend towards precision medicine and targeted therapies. The company's pipeline and commercial activities position it to compete with other biopharmaceutical companies in these areas.

Comparison to Industry Standards

• The $172 million in OGSIVEO revenue for the year is a strong start for a newly launched rare disease drug, putting it in line with similar launches from companies like Blueprint Medicines with Ayvakit.
• The cash position of $461.9 million is healthy for a company of SpringWorks' size and stage, comparable to companies like Deciphera Pharmaceuticals, providing a runway to profitability.
• The projected profitability in the first half of 2026 is an ambitious but achievable goal, similar to timelines projected by other commercial-stage biopharmaceutical companies.

Stakeholder Impact

• Shareholders can expect continued growth and potential profitability in the near future.
• Patients with desmoid tumors and NF1-PN may have access to new treatment options.
• Employees can anticipate continued employment and growth opportunities.
• The company's success benefits suppliers and collaborators through increased business opportunities.

Next Steps

• Continue strong commercial execution of the OGSIVEO launch in the U.S.
• Secure regulatory approval for OGSIVEO in the European Union (EU) and launch OGSIVEO following reimbursement authorization in individual EU countries, beginning with Germany in mid-2025.
• Publish long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors in a peer-reviewed journal by the end of 2025.
• Report initial data from the Phase 2 trial evaluating nirogacestat as a monotherapy in patients with ovarian granulosa cell tumors in the first half of 2025.
• Secure FDA approval in adults and children with NF1-associated plexiform neurofibromas, or NF1-PN (PDUFA: February 28, 2025), and launch in the U.S.
• Obtain regulatory approval in the EU for mirdametinib for the treatment of adults and children with NF1-PN and begin initial launch in 2025.
• File an Investigational New Drug (IND) application for SW-3431 by the end of 2025.

Key Dates